Rapid detection of the irinotecan-related UGT1A1 & 5-fluorouracil related DPYD polymorphism by asymmetric polymerase chain reaction melting curve analysis
•Introduction of a novel PCR melting curve analysis method for rapid detection of DPYD and UGT1A1 polymorphisms related to fluorouracil and irinotecan therapy.•High accuracy and reliability demonstrated through protocol optimization and validation on 28 patients, outperforming Multiplex qPCR, especi...
Gespeichert in:
Veröffentlicht in: | Clinica chimica acta 2024-07, Vol.561, p.119761, Article 119761 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | •Introduction of a novel PCR melting curve analysis method for rapid detection of DPYD and UGT1A1 polymorphisms related to fluorouracil and irinotecan therapy.•High accuracy and reliability demonstrated through protocol optimization and validation on 28 patients, outperforming Multiplex qPCR, especially for heterozygous (TA)n mutations detection.•Intra- and inter-run precision analysis showed low coefficients of variation for melting temperatures (Tms) and high sensitivity with a limit of detection of 0.09 ng/μl of input genomic DNA.•The developed PCR melting curve analysis offers a rapid, simple, and cost-effective solution suitable for clinical laboratories equipped with a fluorescent PCR platform.
Determination of DPYD and UGT1A1 polymorphisms prior to 5-fluorouracil and irinotecan therapy is crucial for avoiding severe adverse drug effects. Hence, there is a pressing need for accurate and reliable genotyping methods for the most common DPYD and UGT1A1 polymorphisms. In this study, we introduce a novel polymerase chain reaction (PCR) melting curve analysis method for discriminating DPYD c.1236G > A, c.1679 T > G, c.2846A > T, IVS14 + 1G > A and UGT1A1*1, *28, *6 (G71R) genotypes.
Following protocol optimization, this technique was employed to genotype 28 patients, recruited between March 2023 and October 2023, at the First Affiliated Hospital of Xiamen University. These patients included 20 with UGT1A1 *1/*1, 8 with UGT1A1 *1/*28, 4 with UGT1A1 *28/*28, 22 with UGT1A1*6 G/G, 6 with UGT1A1*6 G/A, 4 with UGT1A1*6 A/A, 27 with DPYD(c.1236) G/G, 3 with DPYD(c.1236) G/A, 2 with DPYD(c.1236) A/A, 27 with DPYD(c.1679) T/T, 2 with DPYD(c.1679) T/G, 3 with DPYD(c.1679) G/G, 28 with DPYD(c.2846A/T) A/A, 2 with DPYD(c.2846A/T) A/T, 2 with DPYD(c.2846A/T) T/T, 28 with DPYD(c.IVS14 + 1) G/G, 2 with DPYD(c.IVS14 + 1) G/G, and 2 with DPYD(c.IVS14 + 1) G/G, as well as 3 plasmid standards. Method accuracy was assessed by comparing results with those from Sanger sequencing or Multiplex quantitative PCR(qPCR). Intra- and inter-run precision of melting temperatures (Tms) were calculated to evaluate reliability, and sensitivity was assessed through limit of detection examination.
The new method accurately identified all genotypes and exhibited higher accuracy than Multiplex qPCR. Intra- and inter-run coefficients of variation for Tms were both ≤1.97 %, with standard deviations ≤0.95 °C. The limit of detection was 0.09 ng/μL of input genomic DNA.
Our developed PCR melting cu |
---|---|
ISSN: | 0009-8981 1873-3492 1873-3492 |
DOI: | 10.1016/j.cca.2024.119761 |